10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

10X Genomics reports solid earnings, eyes growth through innovation

10X Genomics delivered solid earnings in Q4 2022, with revenue growth and strong product innovation driving market presence and customer engagement.
Despite challenges like operational constraints and margin expectations, the company focuses on financial sustainability and market adaptability for future growth.
Opportunities lie in new sample types exploration, product success with Xenium and Visium HD, and customer response to Chromium Flex, indicating potential for revenue growth and market expansion.
Balanced guidance discussions and a focus on key products position 10X Genomics for strategic growth in 2023, with a global market outlook and emphasis on innovation and customer satisfaction.

10x Genomics reports robust Q1 revenue growth, eyes operational efficiency

10x Genomics delivered strong revenue growth in Q1 2023, driven by spatial portfolio and Chromium consumables, with raised revenue guidance for the year.
The company faces challenges in China and margin pressures but sees opportunities in product enhancements, market expansion, and revenue diversification.
Overall, 10x Genomics is strategically positioned for growth, with a focus on operational efficiency, customer adoption, and revenue optimization.

10X Genomics reports robust Q2 growth amidst China challenges

10X Genomics saw strong revenue growth in Q2 2023, driven by single cell and spatial portfolios.
While facing challenges in China, opportunities lie in expanding applications and clinical adoption.
Operational improvements and product advancements position the company for future growth.
Focus on margin improvement and revenue diversification key for sustained success.

10x Genomics reports robust Q3 revenue growth and strategic realignment

10x Genomics showcased strong revenue growth driven by Xenium's success, with plans to enhance product offerings and rebalance resources for future growth.
Despite challenges in gross margin and flat Chromium revenue, the company remains optimistic about its outlook and growth potential in spatial placements.
Opportunities lie in leveraging Xenium's capabilities, driving consumable revenue through discounts, and focusing on the Chromium franchise for sustained growth.

10x Genomics reports strong Q4 earnings, eyes growth opportunities

10x Genomics anticipates revenue of $670-690 million for 2024.
Guidance philosophy balances upsides and downsides for growth.
Strategic focus on product portfolio and long-term gross margin profile.
Emphasis on investments for future growth and maintaining innovation.

10x Genomics reports Q1 revenue growth, tackles pricing challenges

10x Genomics saw strong revenue growth in spatial but faced challenges with new Chromium technology orders.
The company aims to drive adoption by reducing prices and expanding the total market for single-cell technology.
Customers are showing interest in multiple platforms, setting up genomics infrastructure with various use cases.
Despite obstacles, 10x Genomics remains optimistic about the potential of its technology platforms and market growth.

10X Genomics reports Q3 revenue decline, focuses on growth strategies

10X Genomics faced revenue decline in Q3 due to sales restructuring and cautious customer spending, with full-year revenue expected to decline by 3%. Despite challenges, the company is focused on driving growth through new product launches, evolving commercial structure, and expanding access to single cell analysis. Confidence in the company's path forward remains strong, with expectations for sequential improvements and a focus on long-term opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe.

Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe

NanoString Technologies

Also Files New Suit Against Vizgen's MERSCOPE Products for Patent Infringement PLEASANTON, Calif. , June 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it filed new patent litigation against NanoString Technologies, Inc. (Nasdaq: NSTG) and Vizgen, Inc. in the European Unified Patent Court.

10x Genomics Files Two New Lawsuits Requesting Preliminary Injunctions Against NanoString's CosMx Products

It could be an inflection year for 10x Genomics, one analyst says. TXG stock bounded off a low in October and is now on a seven-month sprint.

How 10x Genomics Provides A View Into The Body's Cellular Warfare

Combining tissue profiling with whole transcriptome spatial analysis and high-plex protein co-detection enables a deeper, more holistic understanding of tissue organization PLEASANTON, Calif. , May 24, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of a new Visium CytAssist Gene and Protein Expression product to expand the breadth of the Visium CytAssist spatial analysis capabilities.

10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay

10x Genomics is seeking additional injunctions to protect its intellectual property PLEASANTON, Calif. , May 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has won an injunction in its patent litigation against NanoString Technologies, Inc. (Nasdaq: NSTG) and NanoString Technologies Germany GmbH.

10x Genomics Wins Permanent Injunction Against NanoString's CosMx Products

Charles River Laboratories

Twist Bioscience Corp

Biology is the study of life. And synthetic biology is the creation of new life for new purposes.

3 DNA Stocks to Buy for the Synthetic Biology Revolution

10x Genomics, Inc. (NASDAQ:TXG ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Cassie Corneau – Head-Investor Relations & Strategic Finance Serge Saxonov – Chief Executive Officer and Co-founder Justin McAnear – Chief Financial Officer Conference Call Participants Dan Arias – Stifel Dan Brennan – Cowen Tejas Savant – Morgan Stanley Patrick Donnelly – Citi Matthew Sykes – Goldman Sachs Kyle Mikson – Canaccord Julia Qin – J.P. Morgan Mason Carrico – Stephens Michael Ryskin – Bank of America Operator Hello, everyone, and welcome to the 10x Genomics' First Quarter 2023 Earnings Conference Call.

10x Genomics, Inc. (TXG) Q1 2023 Earnings Call Transcript

10x Genomics (TXG) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.38 per share a year ago.

10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates

PLEASANTON, Calif. , May 3, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2023.

10x Genomics Reports First Quarter 2023 Financial Results

PLEASANTON, Calif. , April 25, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10, at 2:20 p.m.

10x Genomics to Present at the BofA Securities 2023 Healthcare Conference

PLEASANTON, Calif. , April 12, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023.

10x Genomics to Report First Quarter 2023 Financial Results on May 3, 2023

10x Genomics develops cutting-edge platforms for single-cell and spatial analysis, driving advances in disease research and drug discovery. Despite market fluctuations, their strong product pipeline is expected to fuel revenue growth and expand their customer base.

A Deep Dive Into 10x Genomics, A Promising Portfolio

PLEASANTON, Calif. , Feb. 22, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming 43rd Annual Cowen Healthcare Conference in Boston, Massachusetts.

10x Genomics to Present at the 43rd Annual Cowen Healthcare Conference

10x Genomics, Inc. (NASDAQ:TXG ) Q4 2022 Earnings Conference Call February 15, 2023 4:30 PM ET Company Participants Cassie Corneau - Head, Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer & Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Dan Brennan - Cowen Dan Arias - Stifel Tejas Savant - Morgan Stanley Patrick Donnelly - Citigroup Julia Qin - J.P. Morgan Kyle Mikson - Canaccord Genuity Matt Larew - William Blair Michael Ryskin - Bank of America Matthew Sykes - Goldman Sachs Justin Bowers - Deutsche Bank John Sourbeer - UBS Operator Good afternoon.

10x Genomics, Inc. (TXG) Q4 2022 Earnings Call Transcript

Q4 2022 revenue growth of 9% and FY 2022 revenue growth of 5% over the corresponding periods of 2021 PLEASANTON, Calif. , Feb. 15, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided outlook for 2023.

10x Genomics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Outlook for 2023

Showcases unique power and scalability of Chromium Flex across fresh, frozen and FFPE samples, including data from an 8 million cell experiment on a single run Reinforces performance advantages of Visium CytAssist for unbiased spatial discovery with new data and an exclusive product pipeline, including Visium HD Shares technology roadmap for the Xenium platform, including a broader menu of targeted and customizable panels and the future capability to scale to thousands of plex Launches Xenium Catalyst Program to accelerate researchers' access to high-quality, proof-of-concept in situ data PLEASANTON, Calif. , Feb. 6, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology, today announced a series of new product updates and technology demonstrations that will be presented at the 2023 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Hollywood, Fla.

10x Genomics Demonstrates Breadth, Scale and Leadership at 2023 AGBT General Meeting

CRISPR Therapeutics

Editas Medicine

CRISPR is an acronym which refers to a series of DNA sequences in bacteria and other organisms. Scientists have begun editing genes, including CRISPR,  to try to improve human health.

3 CRISPR Stocks to Buy Now Or You'll Be Kicking Yourself Later

ARK Innovation ETF

Coinbase

DraftKings

Exact Sciences

Invitae

Pacific Biosciences of California

Roblox

Roku

Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

Cathie Wood Is Crushing It This Year Thanks To 9 Stocks

PLEASANTON, Calif. , Jan. 19, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 after market close on Wednesday, February 15, 2023.

10x Genomics to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023

Health Catalyst Inc

NextGen Healthcare Inc

Zacks Medical Info Systems industry stocks like 10x Genomics (TXG), NextGen Healthcare (NXGN) and Health Catalyst (HCAT) are expected to gain as COVID-19 severity fades.

3 Medical Info Systems Stocks Braving Industry-wide Headwinds

PLEASANTON, Calif. , Dec. 28, 2022  /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming 41st Annual J.P.

10x Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference

10x Genomics is targeting larger addressable market opportunities over the mid to long term. The accelerated Xenium launch will bolster the growth potential but may be insufficient to plug a looming shortfall next year.

10x Genomics: Long-Term Growth Potential Marred By Near-Term Funding Risks

AMC Entertainment

Axsome Therapeutics

Chegg

Chart Industries

R1 RCM Inc

Rumble Inc

Twilio

YETI

The stock market witnessed an upward trend last month, a continuation from October.

These Were the 5 Best and Worst Performing Mid-Cap Stocks in November 2022

Began global shipments of Xenium Analyzer, the highest throughput instrument for subcellular In Situ profiling PLEASANTON, Calif. , Dec. 8, 2022 /PRNewswire/ --  10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the first commercial shipments of its Xenium platform for in situ analysis.

10x Genomics Commercially Launches Xenium Platform for In Situ Analysis

Torex Gold Resources Inc. (OTCPK:TORXF) Q3 2022 Earnings Conference Call November 10, 2022 9:00 AM ET Company Participants Dan Rollins - Senior Vice President, Corporate Development & Investor Relations Jody Kuzenko - President and Chief Executive Officer Andrew Snowden - Chief Financial Officer Dave Stefanuto - Executive Vice President, Technical Services & Capital Projects Conference Call Participants Trevor Turnbull - Scotia Capital Michael Fairbairn - Canaccord Genuity Don DeMarco - National Bank Financial Operator Thank you for standing by. This is the conference operator.

News for 10X Genomics Stock (TXG)